Blood Work Education
METABOLIC HEALTH & BLOOD SUGAR
What your fasting glucose, HbA1c, fasting insulin, and HOMA-IR reveal about your metabolism — and why they matter most when read together.
Medically reviewed by Missy Zammichieli, DNP, APRN, FNP-BC ยท Updated March 2, 2026
THE BOTTOM LINE
- • Your blood sugar can look “normal” while your metabolism is already struggling. Insulin rises years before glucose does — and most standard panels never check insulin.
- • This panel catches problems early by measuring fasting insulin and HOMA-IR alongside glucose and A1c. That gives you a head start most people never get.
- • The progression matters: insulin resistance comes first, then elevated insulin, then rising blood sugar, then diabetes. The earlier you catch it, the more you can do about it.
- • Lifestyle changes work. A major prevention trial found that moderate exercise and modest weight loss cut diabetes risk by 58% — more effective than medication.
YOUR BIOMARKERS EXPLAINED
1. Fasting Glucose
What it means for you: This is your baseline blood sugar after an overnight fast. Think of it as a spot-check on how well your body manages fuel when no food is coming in.
Why it matters: Chronically elevated glucose damages blood vessels, nerves, kidneys, and eyes over time. Even mildly elevated fasting glucose — the “prediabetic” range — is linked to higher cardiovascular risk, lower energy, and harder body composition management.
What medical guidelines say:
- Normal: below 100 mg/dL
- Prediabetes: 100 to 125 mg/dL
- Diabetes: 126 mg/dL or higher (confirmed on two tests)
What can push it higher: Insulin resistance, prediabetes, type 2 diabetes, acute stress or illness, certain medications (steroids, some diuretics), liver disease, or not fasting long enough before the draw.
What can push it lower: Extended fasting, excess insulin (from medication or a rare insulin-producing tumor), adrenal insufficiency, or excessive alcohol.
2. Hemoglobin A1c (HbA1c)
What it means for you: If fasting glucose is a snapshot, A1c is the highlight reel. It measures how much sugar has been sticking to your red blood cells over the past 2 to 3 months, giving a rolling average of your blood sugar.
Why it matters: Two people can have the same fasting glucose but very different A1c values. One might have big blood sugar swings after meals that the fasting test never sees. A1c catches those patterns.
What medical guidelines say:
- Normal: below 5.7%
- Prediabetes: 5.7% to 6.4%
- Diabetes: 6.5% or higher (confirmed on a repeat test)
What can push it higher: Sustained elevated blood sugar, iron deficiency anemia (which extends red blood cell lifespan), chronic kidney disease, or heavy alcohol use.
What can make it unreliable: Conditions that shorten red blood cell lifespan — hemolytic anemias, significant blood loss, recent transfusion, or sickle cell trait — can produce falsely low readings.
3. Fasting Insulin
What it means for you: This is the early warning system most standard panels skip. It measures how much insulin your pancreas is pumping out just to keep your blood sugar at baseline.
Why it matters: When your cells start ignoring insulin’s signal (insulin resistance), your pancreas compensates by making more insulin. Your glucose stays normal, but behind the scenes your body is working overtime.
One researcher tested over 14,000 patients and found that elevated insulin frequently shows up years before blood sugar ever rises. Your fasting glucose can look perfect while your insulin tells a completely different story. By the time glucose climbs, the system has been strained for a long time.
Reference points:
- Most labs use a reference range of roughly 2.6 to 24.9 microIU/mL.
- Research consistently links fasting insulin above 8 to 12 microIU/mL with increasing metabolic risk.
- Best interpreted alongside fasting glucose, using the HOMA-IR calculation below.
What can push it higher: Insulin resistance (most common), early type 2 diabetes, PCOS, belly fat, a diet heavy in refined carbs, chronic stress, sleep deprivation, and certain medications.
What can push it lower: Type 1 diabetes, late-stage type 2 diabetes (when the pancreas is exhausted), prolonged fasting, or a very low-carb diet at the time of testing.
4. HOMA-IR (Insulin Resistance Score)
What it means for you: This is a calculated score that answers one question: How hard is your body working to keep your blood sugar normal? A higher number means your system is under more strain.
The formula: (Fasting Insulin x Fasting Glucose) / 405
Why it matters: A person with a fasting glucose of 90 and insulin of 5 is in a completely different metabolic state than someone with a glucose of 90 and insulin of 20 — even though their glucose is identical. HOMA-IR captures that difference.
What the research says:
- ~1.0: Healthy, insulin-sensitive baseline
- Above ~2.0: Early insulin resistance
- Above ~3.0: Significant insulin resistance
What can push it higher: Same factors that raise fasting insulin — insulin resistance, belly fat, sedentary behavior, poor diet, sleep deprivation, chronic stress, PCOS, and certain medications.
Important note: HOMA-IR only reflects your fasting state. It does not capture what happens after meals. It is a valuable screening tool, not the final word.
5. Triglycerides (Metabolic Context)
What it means for you: Triglycerides are fat circulating in your blood. After a meal, your body converts unused calories into triglycerides for storage. Your fasting level shows how efficiently your body clears that fat.
Why it matters for metabolic health: Elevated triglycerides are one of the five criteria for metabolic syndrome. When insulin resistance is present, your liver tends to overproduce triglyceride-rich particles. That is why high triglycerides often show up alongside elevated insulin and HOMA-IR.
The triglyceride-to-HDL ratio is a useful shortcut. A ratio above 3.0 (both in mg/dL) correlates well with insulin resistance. This is handy because both numbers appear on a standard lipid panel.
What medical guidelines say:
- Normal: below 150 mg/dL
- Borderline high: 150 to 199 mg/dL
- Triglycerides above 150 mg/dL are one criterion for metabolic syndrome.
For more on triglycerides and heart health, see the companion article on the Cardiovascular & Lipid Panel.
6. BUN/Creatinine Ratio (Metabolic Context)
What it means for you: This ratio is a quick check on hydration and kidney function. It is included here because dehydration can artificially inflate glucose and other metabolic readings.
A normal ratio (10:1 to 20:1) helps confirm your other results are not being distorted by dehydration or kidney issues. For a deeper look at kidney markers, see the companion article on the Kidney & Electrolyte Panel.
HOW THESE MARKERS TELL A STORY TOGETHER
The real power of this panel is reading these markers as a progression, not isolated numbers.
The problem with checking only glucose: Glucose is a late signal. Research across thousands of patients has shown that most people with normal fasting glucose already have abnormal insulin responses. By the time glucose is high enough to flag, the metabolic problem has been building for years.
The typical progression looks like this:
- Insulin resistance develops. Your cells become less responsive to insulin — driven by belly fat, inactivity, poor diet, or genetics.
- Your pancreas compensates. It ramps up insulin production to keep blood sugar normal. Fasting glucose looks fine. Standard panels show nothing wrong. But fasting insulin is elevated and HOMA-IR is climbing.
- Blood sugar starts to slip. The compensatory system falters. Fasting glucose drifts to 100-125. A1c edges above 5.7%. This is when most people first hear “prediabetes.”
- Type 2 diabetes. Glucose exceeds 126, A1c exceeds 6.5%, and the damage has been accumulating for years.
Steps 1 and 2 are invisible to standard screening. Including fasting insulin and HOMA-IR catches those earlier stages, when you have the most runway to change course.
How triglycerides connect the picture: When you see elevated fasting insulin, rising HOMA-IR, and climbing triglycerides together — even with normal glucose — the pattern strongly suggests a metabolic trajectory that deserves attention.
The composite view: Glucose tells you where you are right now. A1c tells you where you have been over the past 2 to 3 months. Insulin and HOMA-IR tell you how hard your body is working to keep those first two numbers in range. Together, they reveal both the current state and the direction of travel.
WHAT AFFECTS THESE RESULTS
| Factor | How It Impacts Your Numbers |
|---|---|
| Diet | Refined carbs and added sugars drive bigger glucose and insulin spikes. Higher fiber slows glucose absorption. Chronic overconsumption of processed food raises triglycerides and promotes insulin resistance. |
| Exercise | A single workout can improve insulin sensitivity for 24 to 72 hours. Regular training (both lifting and cardio) lowers fasting insulin, improves HOMA-IR, and clears triglycerides — even without weight loss. |
| Sleep | Restricting sleep to 4-5 hours for less than a week measurably reduces insulin sensitivity. Chronic short sleep (under 6 hours) is linked to elevated fasting insulin, higher HOMA-IR, and increased diabetes risk. |
| Stress | Cortisol directly opposes insulin. Chronic stress drives insulin resistance, tells your liver to release extra sugar, and promotes belly fat — all of which worsen metabolic markers. |
| Medications | Steroids raise blood sugar significantly. Some diuretics and beta-blockers can increase glucose modestly. Metformin, GLP-1 agonists, and SGLT2 inhibitors lower glucose through different mechanisms. |
| Meal Timing | Accurate fasting numbers require at least 8 hours without food (ideally 10-12). Eating late, morning calories, or heavy exercise before the draw can all skew results. |
| Body Composition | Belly fat (fat stored around internal organs) is strongly linked to insulin resistance, independent of total body weight. Two people at the same BMI can have very different metabolic profiles depending on where their fat sits. |
COMMON QUESTIONS
“My glucose is normal but my insulin is high — what does that mean?”
This is one of the most important patterns this panel catches. It means your body is producing extra insulin just to keep glucose in the normal range. Think of it like driving with the gas pedal pressed harder than it should be — the speed looks fine, but the engine is working overtime. This does not mean you have diabetes. It means your metabolic system is under more strain than ideal, and it is worth discussing with your provider.
“How is prediabetes defined?”
Prediabetes is diagnosed by any one of three criteria:
- Fasting glucose of 100 to 125 mg/dL
- HbA1c of 5.7% to 6.4%
- 2-hour glucose of 140 to 199 mg/dL on an oral glucose tolerance test
Prediabetes is not a harmless label. Without intervention, roughly 37% of people with prediabetes progress to type 2 diabetes within 4 years.
“Can lifestyle changes actually improve these numbers?”
Yes — and the evidence is some of the strongest in preventive medicine. A landmark prevention trial enrolled over 3,200 people with impaired glucose tolerance. Moderate exercise (about 150 minutes per week) combined with modest weight loss (about 7% of body weight) cut the risk of progressing to type 2 diabetes by 58%. That beat the medication group, which saw a 31% reduction. Follow-up data showed benefits lasting at least 15 years. Fasting insulin, HOMA-IR, triglycerides, and A1c can all improve with exercise, better nutrition, improved sleep, and stress management — often within weeks to months.
“How often should I retest?”
- All markers normal: Every 1 to 3 years depending on age and risk factors.
- Prediabetes or early insulin resistance: 3 to 6 months, especially after making lifestyle changes, to track your trajectory.
- Actively managing a condition: Your provider will set a schedule, often every 3 to 6 months.
Since A1c reflects a 2-to-3-month window, retesting more often than every 3 months does not add much information for that marker.
References
- 1. Araújo J, Cai J, Stevens J. Prevalence of optimal metabolic health in American adults: National Health and Nutrition Examination Survey 2009-2016. Metabolic Syndrome and Related Disorders. 2019;17(1):46-52.
- 2. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215-2221.
- 3. Kraft JR. Detection of diabetes mellitus in situ (occult diabetes). Laboratory Medicine. 1975;6(2):10-22.
- 4. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321.
- 5. Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all-cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953.
- 6. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva: WHO; 2006.
- 7. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia. 2007;50(11):2239-2244.
- 8. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia — when do the risks of diabetes begin? A consensus statement from the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocrine Practice. 2008;14(7):933-946.
- 9. English E, Lenters-Westra E. HbA1c method performance: the great success story of global standardization. Critical Reviews in Clinical Laboratory Sciences. 2018;55(6):408-419.
- 10. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
- 11. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26(12):3320-3325.
- 12. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Annals of Internal Medicine. 2003;139(10):802-809.
- 13. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews. 1997;18(6):774-800.
- 14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
- 15. Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age. BMC Endocrine Disorders. 2013;13:47.
- 16. Tang Q, Li X, Song P, Xu L. Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: developments in research and prospects for the future. Drug Discoveries and Therapeutics. 2015;9(6):380-385.
- 17. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735-2752.
- 18. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881-887.
- 19. McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? American Journal of Cardiology. 2005;96(3):399-404.
- 20. Gaziano JM, Hennekens CH, O’Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997;96(8):2520-2525.
- 21. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 — full report. Journal of Clinical Lipidology. 2015;9(2):129-169.
- 22. Hosten AO. BUN and creatinine. In: Walker HK, Hall WD, Hurst JW, eds. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Boston: Butterworths; 1990:Chapter 193.
- 23. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002;346(6):393-403.
- 24. Ludwig DS, Hu FB, Tappy L, Brand-Miller J. Dietary carbohydrates: role of quality and quantity in chronic disease. BMJ. 2018;361:k2340.
- 25. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065-2079.
- 26. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999;354(9188):1435-1439.
- 27. Cappuccio FP, D’Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2010;33(2):414-420.
- 28. Joseph JJ, Golden SH. Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus. Annals of the New York Academy of Sciences. 2017;1391(1):20-34.
- 29. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes and Endocrinology. 2015;3(11):866-875.